SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2021 / Cilt: 6 - Sayı: 3

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery

Selim GENÇ
Ayşe Sevgi KARADAĞ
Emre GÜLER
Pages
185–190
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The average increase in Schirmer I and FTBUT values was significantly higher in Group 1 than in Group 2 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the effect of topical cyclosporine A (CsA) (Restasis, Abbvie, Lake Bluff, IL, USA) on recurrence rates and tear metrics after pterygium excision and limbal-conjunctival autografting (LCUA) technique in patients with primary pterygium.
📊
Key Findings & Data:Methods: A total of 60 eyes of 60 patients with primary pterygium who underwent pterygium excision and the LCUA technique were evaluated prospectively.
💡
Conclusion & Impact:The average increase in Schirmer I and FTBUT values was significantly higher in Group 1 than in Group 2 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the effect of topical cyclosporine A (CsA) (Restasis, Abbvie, Lake Bluff, IL, USA) on recurrence rates and tear metrics after pterygium excision and limbal-conjunctival autografting (LCUA) technique in patients with primary pterygium. Methods: A total of 60 eyes of 60 patients with primary pterygium who underwent pterygium excision and the LCUA technique were evaluated prospectively. Among them, 30 eyes of 30 patients were treated with topical CsA (Restasis) for 6 months postoperatively (Group 1). The remainder of the patients were assigned to Group 2. The follow-up period was 12 months for each group. The primary outcome measures were a comparison of Schirmer I test and fluorescein tear break-up time (FTBUT) results, the recurrence rate, and postoperative complications. Results: There were no significant differences in age (mean age of Group 1 and 2 was 55.0±9.7 years and 56.3±8.9 years, respectively) or sex between groups (p>0.05). Farmers were the largest group of patients (40.0%). Recurrence of pterygium was observed in 5 (16.6%) eyes in Group 1 and 8 (26.6%) eyes in Group 2. The recurrence rate was not statistically significant between groups (p=0.35). The complication rate was significantly lower in Group 1 compared with that of Group 2 (p=0.02). The average increase in Schirmer I and FTBUT values was significantly higher in Group 1 than in Group 2 (p

🔖

Cite This Article

GENÇ, S., KARADAĞ, A. S., GÜLER, E. (2022). The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery. BEYOGLU EYE JOURNAL, Cilt: 6 - Sayı: 3, 185–190. https://ajindex.com/articles/463200

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999;10:282–8
  2. Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002;43:3430–7
  3. Mutlu FM, Sobaci G, Tatar T, Yildirim E. A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology 1999;106:817–21
  4. Singh G, Wilson MR, Foster CS. Long-term follow-up study of mitomycin eye drops as adjunctive treatment of pterygia and its comparison with conjunctival autograft transplantation. Cornea 1990;9:331–4
  5. Bekibele CO, Baiyeroju AM, Ajayi BG. 5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence. Int J Clin Pract 2004;58:920–3
  6. Oguz H, Basar E, Gurler B. Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Acta Ophthalmol Scand 1999;77:147–50
  7. Fernandes M, Sangwan VS, Bansal AK, Gangopadhyay N, Sridhar MS, Garg P, et al. Outcome of pterygium surgery: analysis over 14 years. Eye (Lond) 2005;19:1182–90
  8. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005;24:80–5
  9. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002;89:298–303
  10. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641–45
  11. Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol 1995;119:189–94
  12. Zhao JC, Jin XY. Immunological analysis and treatment of Mooren's ulcer with cyclosporin A applied topically. Cornea 1993;12:481–8
  13. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997;29:405–8
  14. Gum SI, Kim YH, Jung JC, Kim IG, Lee JS, Lee KW, et al. Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts. Biochem Biophys Res Commun 2017;482:1148–53
  15. Hwang S, Choi S. A comparative study of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery. Korean J Ophthalmol